Cargando...
SB8: A Bevacizumab Biosimilar
SB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy vol...
Gardado en:
| Publicado en: | Target Oncol |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer International Publishing
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7733936/ https://ncbi.nlm.nih.gov/pubmed/33206282 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-020-00776-0 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|